169 related articles for article (PubMed ID: 9265899)
1. History of posttransfusion hepatitis.
Tobler LH; Busch MP
Clin Chem; 1997 Aug; 43(8 Pt 2):1487-93. PubMed ID: 9265899
[TBL] [Abstract][Full Text] [Related]
2. Decrease in reported posttransfusion hepatitis. Contributions of donor screening for alanine aminotransferase and antibodies to hepatitis B core antigen and changes in the general population.
Chambers LA; Popovsky MA
Arch Intern Med; 1991 Dec; 151(12):2445-8. PubMed ID: 1747001
[TBL] [Abstract][Full Text] [Related]
3. [Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy].
Kusendová K; Gavorník P; Sabaka P; Sviteková K
Vnitr Lek; 2016 Jan; 62(1):9-16. PubMed ID: 26967232
[TBL] [Abstract][Full Text] [Related]
4. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
Busch MP; Korelitz JJ; Kleinman SH; Lee SR; AuBuchon JP; Schreiber GB
Transfusion; 1995; 35(11):903-10. PubMed ID: 8604486
[TBL] [Abstract][Full Text] [Related]
5. Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing.
Busch MP
Vox Sang; 1998; 74 Suppl 2():147-54. PubMed ID: 9704438
[No Abstract] [Full Text] [Related]
6. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes.
Mosley JW; Huang W; Stram DO; Nowicki MJ; Hollinger FB; Aach RD; Stevens CE; Barbosa LH; Nemo GJ
Transfusion; 1996 Sep; 36(9):776-81. PubMed ID: 8823449
[TBL] [Abstract][Full Text] [Related]
7. Assessment of screening tests for transfusion-associated non-A non-B hepatitis.
Fleurette F; Durieux P; Battista RN; Benhamou JP; Degos F; Brechot C; Courouce AM; Janot C; Trepo C
Int J Technol Assess Health Care; 1993; 9(4):479-89. PubMed ID: 7507096
[TBL] [Abstract][Full Text] [Related]
8. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg.
Chung HT; Lee JS; Lok AS
Hepatology; 1993 Nov; 18(5):1045-9. PubMed ID: 7693569
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study.
Stevens CE; Aach RD; Hollinger FB; Mosley JW; Szmuness W; Kahn R; Werch J; Edwards V
Ann Intern Med; 1984 Dec; 101(6):733-8. PubMed ID: 6437308
[TBL] [Abstract][Full Text] [Related]
10. Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection.
Behzad-Behbahani A; Mafi-Nejad A; Tabei SZ; Lankarani KB; Torab A; Moaddeb A
Indian J Med Res; 2006 Jan; 123(1):37-42. PubMed ID: 16567866
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.
O'Brien SF; Fearon MA; Yi QL; Fan W; Scalia V; Muntz IR; Vamvakas EC
Transfusion; 2007 Oct; 47(10):1809-15. PubMed ID: 17880605
[TBL] [Abstract][Full Text] [Related]
12. Donor transaminase and recipient hepatitis. Impact on blood transfusion services.
Alter HJ; Purcell RH; Holland PV; Alling DW; Koziol DE
JAMA; 1981 Aug; 246(6):630-4. PubMed ID: 6788964
[TBL] [Abstract][Full Text] [Related]
13. Strategies for the prevention of post-transfusion hepatitis.
Mintz PD
Ann Clin Lab Sci; 1984; 14(3):198-207. PubMed ID: 6428295
[TBL] [Abstract][Full Text] [Related]
14. Safety of the blood supply. Surrogate testing and transmission of hepatitis C in patients after massive transfusion.
Morris JA; Wilcox TR; Reed GW; Hunter EB; Wallas CH; Steane EA; Shotts SD; Vitsky JL
Ann Surg; 1994 May; 219(5):517-25; discussion 525-6. PubMed ID: 7514394
[TBL] [Abstract][Full Text] [Related]
15. Posttransfusion hepatitis B infection after revised screening for hepatitis B.
Arai M; Koshihara K; Takahashi Y; Fukutake K
Int J Hematol; 1999 Jan; 69(1):61. PubMed ID: 10641447
[No Abstract] [Full Text] [Related]
16. Residual transfusion risk for hepatitis B and C in southern Brazil, 1991-99.
Kupek EJ
J Viral Hepat; 2001 Jan; 8(1):78-82. PubMed ID: 11155155
[TBL] [Abstract][Full Text] [Related]
17. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
[TBL] [Abstract][Full Text] [Related]
18. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers.
Barrera JM; Bruguera M; Ercilla MG; Sánchez-Tapias JM; Gil MP; Costa J; Gelabert A; Rodés J; Castillo R
Ann Intern Med; 1991 Oct; 115(8):596-600. PubMed ID: 1909848
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B and C prevalences among blood donors in the south region of Brazil.
Vasconcelos HC; Yoshida CF; Vanderborght BO; Schatzmayr HG
Mem Inst Oswaldo Cruz; 1994; 89(4):503-7. PubMed ID: 8524053
[TBL] [Abstract][Full Text] [Related]
20. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
